Nemesis

About:

Nemesis provides bio and medical device vendors and service providers with Intelligent biosignal processing solutions.

Website: http://www.nemesis.kr

Top Investors: TIPS Program, Capstone Partners, UTC Investment Co., Capstone Partners, K Ground Ventures

Description:

Nemesis provides bio and medical device vendors and service providers with Intelligent biosignal processing solutions. Nemesis has technologies like biosensors, bio-signal processing, and wireless communication, which provide compact, low-power, and accurate semiconductor solutions that anyone can use. Nemesis semiconductor-based intelligent bio signal processing solution can be expanded to diagnose biomarkers in areas such as heart rate, electrocardiogram, blood pressure, and virus detection. Nemesis will do everything possible to improve the quality of our partners' products and services as a result of this.

Total Funding Amount:

3.5B KRW

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seongnam, Kyonggi-do, South Korea

Founded Date:

2017-01-01

Contact Email:

eric.choi(AT)nemesis.kr

Founders:

Number of Employees:

11-50

Last Funding Date:

2021-06-23

IPO Status:

Private

Industries:

© 2025 bioDAO.ai